Paul Feuerstadt
MD, FACG, AGAF
Research & Publications
Biography
News
Research Summary
Research interests focus on C. difficile infection, ischemic bowel disorders and irritable bowel syndrome.
Coauthors
Research Interests
Epidemiology; Treatment Outcome; Outcome Assessment, Health Care
Selected Publications
- Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIKraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, Khanna S, Berenson C, Wang E, Cohen S, Korman L, Lee C, Kelly C, Odio A, Cook P, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi D, Hasson B, McGovern B, von Moltke L, Pardi D. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious Diseases And Therapy 2024, 1-17. PMID: 38941068, DOI: 10.1007/s40121-024-01007-z.
- Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infectionSehgal K, Feuerstadt P. Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection. Frontiers In Microbiomes 2024, 3: 1399440. DOI: 10.3389/frmbi.2024.1399440.
- The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and BeyondAllegretti J, Khanna S, Mullish B, Feuerstadt P. The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond. Gastroenterology 2024 PMID: 38754739, DOI: 10.1053/j.gastro.2024.05.004.
- Mo1345 ACUTE VASCULAR INTESTINAL DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE: A NATIONAL ANALYSISRizwan R, Chaar A, Sehgal K, Richter T, Nawaz A, Patel S, Feuerstadt P. Mo1345 ACUTE VASCULAR INTESTINAL DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE: A NATIONAL ANALYSIS. Gastroenterology 2024, 166: s-1033. DOI: 10.1016/s0016-5085(24)02849-x.
- Sa1898 RACIAL DISPARITIES IN PATIENTS HOSPITALIZED WITH CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDYChaar A, Rizwan R, Patel S, Sehgal K, Richter T, Nawaz A, Feuerstadt P. Sa1898 RACIAL DISPARITIES IN PATIENTS HOSPITALIZED WITH CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY. Gastroenterology 2024, 166: s-569-s-570. DOI: 10.1016/s0016-5085(24)01783-9.
- Su1009 RACIAL DISPARITIES IN ACUTE VASCULAR INTESTINAL DISEASES: A NATIONAL ANALYSISSehgal K, Chaar A, Rizwan R, Richter T, Feuerstadt P. Su1009 RACIAL DISPARITIES IN ACUTE VASCULAR INTESTINAL DISEASES: A NATIONAL ANALYSIS. Gastroenterology 2024, 166: s-634-s-635. DOI: 10.1016/s0016-5085(24)01916-4.
- Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United StatesLembo A, Cash B, Lu M, Terasawa E, Terreri B, Du S, Ayyagari R, Feuerstadt P, Moshiree B, Westermeyer B, Pi S, Boules M. Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States. Clinical And Translational Gastroenterology 2024, 15: e00687. PMID: 38357940, PMCID: PMC11124638, DOI: 10.14309/ctg.0000000000000687.
- Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile InfectionFeuerstadt P, Allegretti J, Dubberke E, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke L, LaPlante K, Garey K, Khanna S. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious Diseases And Therapy 2024, 13: 221-236. PMID: 38236515, PMCID: PMC10828144, DOI: 10.1007/s40121-023-00907-w.
- Erratum: Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection.Feuerstadt P, LaPlante K. Erratum: Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection. The American Journal Of Gastroenterology 2024 PMID: 38180907, DOI: 10.14309/ajg.0000000000002649.
- Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile InfectionFeuerstadt P, LaPlante K. Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection. The American Journal Of Gastroenterology 2024, 119: s22-s26. PMID: 38153222, DOI: 10.14309/ajg.0000000000002582.
- Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infectionKnapple W, Yoho D, Sheh A, Thul J, Feuerstadt P. Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection. Therapeutic Advances In Gastroenterology 2024, 17: 17562848241239547. PMID: 38529070, PMCID: PMC10962041, DOI: 10.1177/17562848241239547.
- Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.Feuerstadt P, Crawford C, Tan X, Pokhilko V, Bancke L, Ng S, Guthmueller B, Bidell M, Tillotson G, Johnson S, Skinner A. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3. Journal Of Clinical Gastroenterology 2023 PMID: 38019088, DOI: 10.1097/mcg.0000000000001947.
- 366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical TrialFeuerstadt P, Blount K, Guo A, Yang M, García-Horton V, Fillbrunn M, Tillotson G, Gao Y, Dubberke E, Garey K. 366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial. Open Forum Infectious Diseases 2023, 10: ofad500.436. PMCID: PMC10676825, DOI: 10.1093/ofid/ofad500.436.
- The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficileSehgal K, Feuerstadt P. The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile. Translational Gastroenterology And Hepatology 2023, 8: 31-31. PMID: 38021361, PMCID: PMC10643224, DOI: 10.21037/tgh-23-46.
- 197 Annual Hospitalization and Mortality Trends Among Patients With Sickle Cell Disease and Clostridioides difficile InfectionSharma P, Hundt M, Aguilar R, Nader M, Yadav S, Rawlings R, Feuerstadt P. 197 Annual Hospitalization and Mortality Trends Among Patients With Sickle Cell Disease and Clostridioides difficile Infection. The American Journal Of Gastroenterology 2019, 114: s120-s121. DOI: 10.14309/01.ajg.0000590320.20381.01.